Review

Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects

Fanny Monneaux and Sylviane Muller

CNRS, Immunologie et Chimie Thérapeutiques, Institut de Biologie Moléculaire et Cellulaire, 15 rue René Descartes, 67000 Strasbourg, France

Corresponding author: Sylviane Muller, S.Muller@ibmc.u-strasbg.fr

Published: 30 June 2009

Arthritis Research & Therapy 2009, 11:234 (doi:10.1186/ar2711)

© 2009 BioMed Central Ltd

Abstract

The prognosis of patients with systemic lupus erythematosus has greatly improved since treatment regimens combining corticosteroids and immunosuppressive medications have been widely adopted in therapeutic strategies given to these patients. Immune suppression is evidently efficient but also leads to higher susceptibility to infectious and malignant diseases. Toxic effects and sometimes unexpectedly dramatic complications of current therapies have been progressively reported. Identifying novel molecular targets therefore remains an important issue in the treatment of lupus. The aim of this review article is to highlight emerging pharmacological options and new therapeutic avenues for lupus with a particular focus on non-antibody molecular strategies.

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by unpredictable exacerbations and remissions with diverse clinical manifestations. The latter may range from nonspecific symptoms, such as fatigue and arthralgia, to life-threatening renal and neurological manifestations. Women of childbearing age and certain minorities are disproportionately affected. A prevalence of several hundred thousand patients with lupus has been estimated in the United States – it may in fact approach 1 million to 2 million individuals according to the Lupus Foundation of America – and almost the same figures are given in Europe.

Compared with previous decades, when the 4-year survival was estimated to be just 50% in the 1950s, patients with SLE today are less likely to die from the disease itself (the 15-year survival rate is now estimated to be around 80 to 85%). This notable improvement comes from the introduction in the 1960s and 1970s of key immunosuppressive drugs such as azathioprine, methotrexate, cyclophosphamide, and cyclosporine, and more recently by the use of mycophenolate mofetil (CellCept) that appears effective with fewer side effects. At present, antimalarials (hydroxychloroquine), corticosteroids and cytotoxic drugs are classically used as medication in SLE. It has to be recognized, however, that significant well-known adverse effects of these conventional drugs may severely counterbalance the clinical outcomes of treated patients, who can develop recurrent infections and in some cases malignant diseases. These major side effects are due to the generalized nature of the immunosuppression. There are also concerns about still unpredictable lupus flares in disease remissions and about a non-negligible number of nonresponders sometimes affected by severe forms of lupus such as catastrophic antiphospholipid syndrome.

For all these reasons, and particularly in the past 6 to 7 years, intense and collective research has led to the development of more targeted approaches that are currently under evaluation for treating patients with lupus. A number of drugs in late-stage clinical development hold promise for treating the disease. These drugs are mostly mAbs targeting B cells, such as rituxan (rituximab) or ocrelizumab (mAbs to CD20 antigen on B cells; both in phase III trial by Genentec, San Francisco, CA, USA), LymphoStat-B (belimumab; phase III trial by Human Genome Sciences, Rickville, IN, USA) that targets B-lymphocyte stimulator, and epratuzumab, a humanized antibody (Ab) that targets the CD22 receptor on B cells (phase IIb trial by UCB Pharma, Colombes, Belgium).

The present report will not concentrate on these therapeutic Abs that have been described in recent comprehensive reviews (for example [1,2]), but will rather focus on fusion...
proteins, peptides and small molecules that represent excellent alternative tools for immune intervention in lupus.

**Novel targets in the treatment of lupus patients: ongoing therapeutic trials**

Molecular targeted therapies have created an encouraging trend in the treatment of lupus. In recent years, drugs targeting cell surface molecules, intracellular components, hormones or autoantigens have been clinically evaluated (Table 1 and Additional File 1).

**Cell surface-expressed molecules**

Based on our improving knowledge of cellular abnormalities in lupus, a variety of T-cell and B-cell surface-expressed molecules can conceptually be targeted to bypass or correct these dysfunctions. In addition to mAbs that target key cell-surface markers such as CD3, CD4, CD20, CD22, CD25 (IL-2 receptor alpha), CD52 (present on the surface of mature lymphocytes), CD40 and CD154/CD40 ligand or certain integrins, therefore, potentially efficient molecules have been developed to interfere with cell-surface components, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4)/CD152, certain members of the TNF family or members of the heat shock protein family.

Abatacept (CTLA-4 immunoglobulin; Orencia, developed by Bristol-Myers-Squibb, Princeton, NJ, USA) is a fusion protein that contains the extracellular domain of the co-stimulator receptor CTLA-4 molecule and an IgG Fc domain. Abatacept is thought to inhibit stimulation of T cells by blocking the interaction of CD80/CD86 (B7-1/B7-2) with CD28 (Figure 1). This drug, which is approved to treat rheumatoid arthritis, has been evaluated in association with prednisone in a phase Ib clinical trial for SLE, and a phase III trial for SLE is currently recruiting participants. The same company also develops belatacept (LEA29Y), which differs from abatacept by only two amino acid residues.

Atacicept, a TACH-Ig fusion protein currently evaluated in placebo-controlled phase II/III clinical trials under the sponsorship of Zymogenetics/Merck Serono (Seattle, WA, USA and Geneva, Switzerland), targets B-lymphocyte stimulator and APRIL, two members of the TNF family, which promote B-cell survival. In an earlier phase Ib trial, patients treated with atacicept demonstrated dose-related decreases in immunoglobulin and in mature and total B-cell numbers. There was no change in the numbers of T cells, natural killer cells, or monocytes. The drug was shown to be safe and well tolerated with no serious adverse effects. There was also a positive trend in SELENA – Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores and in complement levels in treated patients [3].

Intensive research has been focused on an immunosuppressant, 15-deoxyspergualin (gusperimus; Table 1 and Additional File 1), and several active and less toxic analogues of this molecule, such as LF08-0299 (tresperimus). These molecules, the action mechanism of which is not fully elucidated, interact with the constitutive HSC70/hsp73 heat shock protein, expressed both intracellularly and at the membrane, leading among other effects to the inhibition of NF-κB nuclear translocation. 15-Deoxyspergualin was shown to suppress the progression of polyclonal B-cell activation and lupus nephropathy in lupus-prone MRL-1pr/lpr mice [4]. In a short trial, however, two out of three treated SLE patients showed nonsevere infectious episodes after 15-deoxyspergualin treatment [5].

**Compounds targeting intracellular components**

Targeting intracellular processes, such as signaling, apoptosis or the cell cycle, may also represent an efficient therapeutic method in SLE.

FKBP12-binding agents such as rapamycin (sirolimus, rapamune) and tacrolimus (FK506), widely used as immunosuppressive agents, may represent interesting drugs to slow down lupus disease progression. These two molecules (Table 1, Additional File 1 and Figure 1) bind to the specific cytosolic binding-protein FKBP12: but while tacrolimus complexed to FKBP12 inhibits the Ca2+-dependent phosphatase calcineurin, rapamycin-FKBP12 binds to and inactivates mammalian target of rapamycin, a pivotal regulator of cell growth and proliferation for many cell types. Other effects of rapamycin include apoptosis, inhibition of T-cell activation, inhibition of cell migration, and changes in membrane trafficking. The fact that tacrolimus has been shown to reduce the incidence of skin lesions in MRL-1pr/lpr mice [6] and that it is used to control the symptoms of eczema led to the proposal that tacrolimus might represent an alternative to topical corticosteroid treatment in cutaneous lupus. It has been recently reported that tacrolimus effectively presents a significant efficacy, but randomized controlled trials are needed to evaluate its safety and cost-effectiveness [7]. Rapamycin was shown to prevent lupus in both NZBW/F and MRL-1pr/lpr mice, and preliminary results in nine SLE patients revealed that rapamycin appears safe and effective in patients who have been refractory to conventional treatments [8]. A phase II study conducted by Wyeth Pharmaceuticals (Madison, WI, USA) with the aim of prospectively determining the therapeutic efficacy and action mechanisms of rapamycin in patients with SLE is currently recruiting participants.

Induction of specific apoptosis that selectively kills autoreactive or inflammatory cells should also be considered to slow down disease progression. As lupus T cells are abnormally resistant to the induction of apoptosis, targeting this population may represent an interesting alternative. Datta and colleagues have demonstrated that resistance to apoptosis of lupus T cells is related to an upregulation of cyclooxygenase 2, an enzyme involved in the formation of prostanooids [9]. Celecoxib (celebrex, celebra, controlled by Pfizer; Table 1 and Additional File 1), a cyclooxygenase-2 inhibitor, was
### Table 1

**Compounds of interest as new tools for the treatment of systemic lupus erythematosus**

| Compound                  | Product description                                                                 | Type of study                                                                 | Results/comments                                                                                                                                                                                                 | Reference |
|---------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Atacicept                 | Fusion protein (TACI-Ig) B-lymphocyte stimulator inhibition                           | Phase Ib, double-blind, placebo-controlled, dose-escalating trial. Patients with mild to moderate SLE were enrolled. | Dose-dependent reduction in immunoglobulin levels and B-cell numbers. Well tolerated.                                                                                                                                | [3]       |
| 15-Deoxyspergualin or gusperimus | Binds to HSC70/hsp73 heat shock protein                                                | Case report: 3 SLE patients, safety evaluation. Treatment was performed by 9 cycles (1 cycle = 15-deoxyispergualin administration for 14 days with a break of 7 days). | 15-Deoxyspergualin was well tolerated but 2/3 patients had nonsevere infectious episodes.                                                                                                                         | [5]       |
| FK506 or Tacrolimus       | Inhibition of calcineurin                                                             | Retroprospective review: analysis of 5 studies (only one randomized controlled trial), including a total of 60 SLE patients with cutaneous lesions. | Efficacy in cutaneous lesions of SLE, but weaker efficacy in subacute cutaneous LE or in discoid LE. Studies involving only a small number of patients and no control group. | [7]       |
| Rapamycin/sirolimus/rapamune | mTOR inactivation                                                                   | Open-label study: 9 SLE patients treated unsuccessfully with immunosuppressive medications. Rapamycin was given orally (2 mg/day). | Reduction of BILAG score, of SLEDAI score and of prednisolone use compared with pre-rapamycin treatment.                                                                                                        | [8]       |
| Celecoxib or celebrex     | Cyclooxygenase-2 inhibition                                                           | Retrospective review of medical records for 50 patients treated with celecoxib. | Diminution of inflammation and good safety profile.                                                                                                                                                                 | [10]      |
| Pentoxiphylline           | Xanthine-derivative phosphodiesterase inhibitor                                      | Open-label study: 11 SLE patients with refractory nephritis: class III, IV or V, proteinuria ≥3 g/24 hours. | Decrease of proteinuria (from 5.5 to 2.0, P = 0.003). No patients discontinued the study due to side effects.                                                                                                     | [13]      |
| Tamoxifen                 | Estrogen antagonist                                                                  | Double-blind crossover trial: 11 females with stable SLE.                     | No improvement of disease activity and 2 patients deteriorated.                                                                                                                                                     | [18]      |
| DHEA or prasterone        | Androgen                                                                            | Review: analysis of randomized controlled trials (7) comparing DHEA with a placebo in SLE patients (842 participants). | Little clinical effect on disease activity for patients with moderate disease.                                                                                                                                 | [20]      |
| Fulvestrant or faslodex   | Estrogen receptor downregulator                                                      | Double-blind, placebo-controlled: 20 premenopausal SLE women with moderate SLEDAI received either 250 mg fulvestran intramuscularly for 12 months (10 patients) or placebo (10 patients). | Improvement of SLEDAI but not of serological markers, routine laboratory tests nor bone density. Medications for lupus reduced in the fulvestrant group.                                                                 | [21]      |
| Bromocriptine             | Dopamine agonist inhibition of prolactine secretion                                  | Open-label trial: 7 active SLE patients treated daily during 6 to 9 months.   | Serum prolactine and anti-dsDNA suppressed, SLEDAI decreased (16 to 5.9).                                                                                                                                          | [24]      |

**Continued overleaf**
shown to induce apoptosis of lupus T cells ex vivo, leading in co-cultures to the inhibition of autoAb production [9]. Results from two clinical trials including SLE patients revealed that the use of celecoxib, which presents a good safety profile, was beneficial with, notably, a decrease of generalized inflammation and a decreased SLEDAI score [10,11].

Cyclic nucleotide phosphodiesterase isoenzymes (11 families), dedicated to cyclic AMP/GMP hydrolysis, play an important role in physiological responses. The PDE4 family was described as one of the major families controlling inflammation, and over the past years the development of PDE4 inhibitors as anti-inflammatory drugs has been a major focus of pharmaceutical research. The administration of pentoxiphylline (Table 1 and Additional File 1), a xanthine derivative and well-known phosphodiesterase inhibitor, into MRL-1pr/lpr mice resulted in a diminution of clinical parameters of the disease [12]. In an open-label study including 11 lupus patients with renal manifestations, pentoxiphylline was demonstrated to reduce proteinuria [13]. Further investigations should thus be undertaken to validate this interesting observation as all patients were given immunosuppressants concomitantly.

**Agents that modulate the hormonal pathway**

Both sex steroid estrogen and pituitary hormones such as prolactin are known to modulate autoimmunity and are thus supposed to play a role in SLE. The involvement of hormones in disease pathogenesis is supported by several observations: the prevalence of SLE is far higher in females than in males; the onset of lupus often occurs in young, premenopausal women; and males with SLE have low levels of testosterone. The reduced secretion of anti-DNA Abs following testosterone treatment highlights the critical role of estrogen in the disease.

**Modulation of sex steroid hormones**

Treatment of NZB/W female mice with the estrogen antagonist tamoxifen (Table 1 and Additional File 1) significantly reduces anti-DNA Ab production, ameliorates glomerulonephritis and prolongs survival [14,15]. In MRL-1pr/lpr female mice, tamoxifen alleviates disease activity, and treatment with the selective estrogen receptor modulator LY139478 (Table 1 and Additional File 1) improves survival and retards the progression of glomerulonephritis [16,17]. An open-label study of 11 patients with SLE, however, did not demonstrate any benefits of tamoxifen in ameliorating the clinical and serological activity of SLE [18].

Improvement of the lupus disease in animal models with androgen administration led investigators to also consider dehydroepiandrosterone (Table 1 and Additional File 1) for therapeutic use in lupus patients. Dehydroepiandrosterone (DHEA) is a naturally occurring steroid and possesses both endocrine and immunomodulatory effects. Interestingly, serum levels of DHEA are decreased in SLE patients [19]. Several clinical studies have thus investigated the effect of DHEA (G-701, prestara, prasterone) administration in lupus patients. A comparison of these studies revealed that whereas DHEA supplementation improved quality of life and glucocorticoid requirements, the impact on disease activity was inconsistent [20].

A double-blind placebo-controlled clinical trial recently reported encouraging results in SLE women treated with an estrogen-selective receptor downregulator named fulvestrant (faslodex, developed by AstraZeneca Pharmaceuticals, London, UK; Table 1 and Additional File 1). In patients who received 250 mg fulvestrant intramuscularly for 12 months, the SLEDAI score improved significantly and conventional medications could be reduced [21].

**Inhibition of prolactin**

An increased frequency of hyperprolactinemia is observed in patients with SLE, and elevated prolactin levels have been correlated with clinical disease [22]. Prolactin administration has been demonstrated to accelerate disease progression in

---

**Table 1 (continued)**

| Compound | Product description | Type of study | Results/comments | Reference |
|----------|---------------------|---------------|-----------------|-----------|
| LJP394/abetimus sodium/rquent | Toleragen molecule; 4 strands of ds-oligonucleotides (20-mer) linked through a triethylene glycol-based platform | Phase III, randomized, placebo-controlled trial: 317 SLE patients with a history of renal flares and anti-dsDNA levels >15 IU/ml. Patients received 100 mg/week for up to 22 months. | Abetimus did not prolong time to renal flare, time to initiation of high-dose corticosteroid and/or cyclophosphamide treatment, or time to major SLE flare, but decreased anti-dsDNA antibody levels ($P < 0.0001$). | [27] |
| Lupuzor RIIHMVYRSKRG PRGYAFIEY | 21-mer peptide P140 (phosphoserine at position 140) | Phase IIa: open-label, dose-escalating trial. 20 patients with moderate SLE were enrolled. Lupuzor was given subcutaneously (200 μg or 1 mg). | Diminution of anti-dsDNA antibody levels and of SLEDAI score in the group that received 200 μg peptide. | [31] |

Published trials only are presented. BILAG, British Isles Lupus Assessment Group; DHEA, dehydroepiandrosterone; ds, double-stranded; mTOR, mammalian target of rapamycin; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
murine models of lupus (reviewed in [23]). Taken together, these data showed that downregulation of the prolactin production may represent an interesting way to treat SLE. As prolactin secretion is inhibited by dopamine released from the hypothalamus, the efficacy of bromocriptine (Table 1 and Additional File 1), which is a dopamine agonist, was evaluated in lupus. In an open-label trial including seven SLE patients, it was shown that bromocriptine (3.75 to 7.5 mg/day for 6 months) suppressed prolactin levels in all subjects and improved clinical measurements in six of the seven treated patients [24]. A double-blind, placebo-controlled study of low-dose bromocriptine therapy (2.5 mg/day) showed a significant decrease in prolactin levels associated with a significant decrease in disease activity [25]. A pilot clinical trial was recently conducted to explore the potential role of oral bromocriptine during pregnancy [26]. Results showed that bromocriptine may play a role in protecting pregnant lupus patients from maternal and fetal complications.

**Autoantigens**

Among the outcome measures (endpoints) to be considered in SLE trials are biomarker manifestations (for example, anti-dsDNA Abs). During the past decade, a number of investi-
gators have thus explored targeted strategies involving auto-
antisens in order to subvert or block key steps of the disease.
Promising data have been raised in murine models of lupus,
and a few therapeutic trials are currently in progress.

Two peptides and one peptide construct have reached
advanced clinical trials in lupus patients. The efficacy of the
first peptide, hCDR1 (edratide, TV-4710), although extremely
promising in lupus mice, was found to be safe and well
tolerated but did not meet its primary endpoint in a
randomized, double-blind, placebo-controlled phase II clinical
trial conducted by Teva (Petach Tikva, Israel) in 340 SLE
patients who received the peptide weekly by a subcutaneous
route (PRELUDE trial).

The results of a second candidate, abetimus sodium (LJP394,
riquet) – evaluated in a randomized, placebo-controlled,
multicenter phase III trial – have been recently published [27]
(Table 1 and Additional File 1). Abetimus is a synthetic water-
soluble molecule consisting of four double-stranded oligo-
dekyoxyribonucleotides each attached to a nonimmunogenic
triethylene glycol backbone, a proprietary carrier platform
[28]. Originated by La Jolla Pharmaceuticals (San Diego, CA,
USA), abetimus is an immunomodulating agent that induces
tolerance in B cells directed against dsDNA by cross-linking
surface Abs potentially responsible for lupus nephritis. The
recent reported data showed that abetimus administrated at
100 mg/week for up to 22 months to patients with lupus
nephritis significantly reduced anti-dsDNA Ab levels but did
not significantly prolong the time to renal flare when compared
with placebo. Although multiple positive trends in
renal endpoints were observed in the abetimus treatment
group [27], it has been recently decided to halt further clinical
trials of this drug in lupus.

A third peptide-based strategy involving an autoantigen seg-
ment, peptide P140 (IPP-201101, lupuzor), holds promise
(Table 1 and Additional File 1). This phosphorylated peptide is
recognized by T cells from MRL-lpr/lpr
mice was found to significantly improve their clinical and
biological manifestations and prolonged their survival, while
the nonphosphorylated analogue did not. The P140 peptide
was included in phase I and phase II clinical trials conducted
by ImmPharma (Mulhouse, France). Peptide P140 was found
to be safe and well tolerated by subjects, and significantly
improved the SLEDAI score and biological status of lupus
patients who received three subcutaneous doses of 200 μg
peptide [31]. P140 peptide is currently being evaluated in a
phase IIb, double-blind, placebo-controlled, dose-ranging
study in Europe and Latin America to confirm the beneficial
effects observed in the phase Ila trial.

**Experimental agents for lupus therapy**

Besides agents that are presently evaluated in clinical trials in
patients with lupus, there are also a number of experimental
compounds used with success in murine studies that deserve
particular attention. They are described below because
hopefully some of them represent interesting candidates for
future clinical trials.

**Compounds targeting intracellular components**

Spleen tyrosine kinase, a cytoplasmic tyrosine kinase, is a key
mediator of immunoreceptor signaling in a variety of cells,
including B cells, mast cells, macrophages platelets, and
naive mature T cells. The spleen tyrosine kinase-specific
inhibitor R406 (converted from the prodrug R788 developed
by Rigiel Pharmaceuticals Inc., San Francisco, CA, USA),
given orally, reduced the renal pathology and prolonged
survival of prediseased NZB/W mice, and, more importantly,
of mice with established lupus nephritis [32]. Interestingly,
signaling in lupus T cells is not effected by ZAP-70 but
replaced by spleen tyrosine kinase, leading to an increased
calcium response upon T-cell receptor stimulation [33].

Although no clinical data from SLE lupus are yet available,
results from a recent phase II clinical trial including 189
patients with rheumatoid arthritis are encouraging [34]. The
use of small molecules inhibiting intracellular mitogen-
activated protein kinase and phosphoinoside 3-kinase
(enzymes that generate phosphatidylinositol diphosphate and
triphosphate after receptor stimulation) signaling pathways
has also been envisaged. Although the extracellular signal-
regulated kinase (a serine/threonine protein kinase of the
mitogen-activated protein kinase family) inhibitor FR180204
was recently described as a new therapeutic approach in
rheumatoid arthritis [35], the use of such molecules in lupus
could be hampered by the fact that the mitogen-activated
protein kinase/extracellular signal-regulated kinase
pathway is reduced in lupus T cells [36]. In contrast, several
studies have demonstrated that phosphoinoside 3-kinase
gamma plays a crucial role in SLE, and encouraging results
have been obtained using MRL-lpr/lpr mice treated with
selective phosphoinoside 3-kinase gamma inhibitors, such as
AS605240 (a specific p110γ inhibitor) [37]. Promising
molecules targeting the phosphoinoside 3-kinase gamma
pathway that have entered clinical trials for cancer therapy, inflam-
mation and coronary heart disease are described in a recent
review [38].

Molecules able to interfere with cell cycle should also be
considered as potential candidates in the development of
new lupus therapies. Cell cycle progression is controlled by
the activation of a heterodimer, formed by cyclins (regulatory
subunits) associated with cyclin-dependent kinases (catalytic
subunits; Figure 1). The effect of seliciclib (CYC202; Table 1
and Additional File 1), a cyclin-dependent kinase inhibitor that
is a trial drug currently tested in patients with solid tumors
and B-cell malignancies, was recently evaluated in NZB/W
lupus mice [39]. When administered in the early stages of the
disease, seliciclib was shown to delay the development of
proteinuria, to reduce the production of anti-dsDNA Abs, and
to prolong survival. A similar observation was made with the use of a cell cycle peptide inhibitor, the p21\textsubscript{Waf/Cip1} mimic [40]. As the expression of the cyclin-dependent kinase inhibitor p21\textsubscript{Waf/Cip1} is decreased in lymphocytes of lupus patients [41], the use of such inhibitors could represent an attractive route for treatment.

Other agents for which efficacy has been already established in murine models of lupus may offer interesting therapeutic avenues in the future. The ubiquitin–proteasome pathway is involved in intracellular protein turnover and its function is crucial to cellular homeostasis. Bortezomib (a proteasome inhibitor marketed as Velcade by Millennium Pharmaceuticals, Cambridge, MA, USA; Table 1 and Additional File 1) has thus been successfully used in multiple myeloma. By blocking I\kappa B degradation, bortezomib induces the inhibition of NF-\kappa B and increases apoptosis of leukemia cells. These results led investigators to evaluate the efficacy of bortezomib for the depletion of plasma cells in lupus. Bortezomib treatment of NZB/W and MRL-lpr/lpr lupus mice efficiently depleted plasma cells, reduced autoAbs production, ameliorated glomerulonephritis and prolonged survival [42]. It was recently shown that inhibiting proteasome does induce the apoptosis of activated CD4\textsuperscript{+} T cells, indicating that targeting proteasome activity in lupus may represent an interesting molecular strategy for targeting both autoreactive B cells and T cells.

Histone acetylation is an important regulator of gene expression, and therefore interfering with histone deacetylation could represent an interesting strategy to modulate altered gene expression in lupus. Histone deacetylase inhibitors have been used to reduce the disease in murine models of lupus. In MRL-lpr/lpr mice, tricostatin A (Table 1 and Additional File 1) was found to decrease inflammatory cytokine production by splenocytes and reduce renal disease [43]; suberoylanilide hydroxamic acid was also shown to modulate lupus progression [44]. These experimental data suggest that histone deacetylase inhibitors might have therapeutic interest to treat SLE.

**Compounds inhibiting soluble molecules**

In lupus, the loss of self-tolerance leads to the persistence and activation of autoreactive B cells and T cells with the consequent abnormal secretion of cytokines and production of autoAbs. The formation of immune complexes and the activation of the complement pathway also play a major role in disease pathogenicity. These soluble proteins are thus interesting target candidates for the development of novel lupus therapies.

The activation of the complement pathway in lupus amplifies both immune and inflammatory responses and is involved in the renal pathology. Apart from the use of anti-C5 monoclonal Abs, the recent development of a molecule able to interfere with both alternative and classical complement pathways and that protects MRL-lpr/lpr mice from the disease is encouraging [45]. This therapeutic agent, named CR2-Cry, corresponds to a fusion protein that links the C3-binding region of complement receptor 2 (CR2) to the complement receptor 1-related protein y (Cryy). Cryy is similar to human complement receptor 1 and inhibits C3 convertases of all pathways. Complement inhibition in MRL-lpr/lpr mice with Cryy as a recombinant protein (Cryy-Ig) protected animals from renal disease but had no effect on survival [46], whereas CR2-Cry treatment reduced glomerulonephritis, renal vascuiritis, skin lesions and autoAb production associated with a significant survival benefit. Importantly, and contrary to observations with Cryy-Ig, CR2-Cry did not increase the levels of circulating immune complexes, offering another advantage to its development for controlling the human disease.

Several cytokines have been identified as major targets in lupus, leading to the development of numerous mAbs, some of them currently used in therapy or under clinical evaluation. Another approach was recently developed, based on active immunotherapy, which consists of inducing Abs able to neutralize the interaction of the self-cytokine to its receptor. In a mouse model for rheumatoid arthritis (transgenic mice expressing human TNF\alpha), it was demonstrated that vaccination with a biologically inactive but immunogenic human TNF\alpha derivative (keyhole limpet hemocyanin–human TNF\alpha heterocomplex), led to the production of high titers of Abs that neutralize human TNF\alpha bioactivity. Moreover, immunized transgenic mice were protected from spontaneous arthritis [47]. As cytokine network dysregulation is highly complex in lupus, further investigations are needed to evaluate whether this strategy may be advantageous in SLE in the future.

FTY720 (fingolimod), a high-affinity agonist of sphingosine-1-phosphate type 1 receptor that induces the internalization of the receptor, thus depriving cells from normal binding of soluble sphingosine-1-phosphate type 1, is effective in several murine models of lupus. The agonist was found to suppress the development of autoimmunity and to prolong the lifespan of female MRL-lpr/lpr mice [48]. FTY720 acts primarily by sequestering lymphocytes within peripheral lymphoid organs, rendering them incapable of migrating to the sites of inflammation. Phase I, phase II and phase III clinical trials have been conducted mostly in patients with multiple sclerosis (Novartis, Basel, Switzerland) (reviewed in [49]). Results are not yet available for patients with SLE.

**Autoantigens**

As described above, peptides encompassing autoantigen sequences represent interesting tools to specifically target autoreactive cells. Beside the peptides currently evaluated for their efficacy in lupus, other peptides hold promise as they gave interesting results in murine models of lupus.

Peptides corresponding to complementary-determining regions (CDRs) in the heavy chain variable domain of autoAbs to
dsDNA have thus been used with remarkable efficacy in NZB/W mice. These are, for example, the so-called 15-mer pCONS peptide, a consensus of sequences derived from the immunoglobulin heavy chain variable region (CDR1 and second framework FR2) of several different NZB/W Abs to DNA [50], or peptides derived from the sequence of the CDR1 and CDR3 (pCDR1, pCDR3) of a murine anti-DNA mAb that bears the so-called 16/6 idiootype [51]. Tolerization of NZB/W mice to monthly intravenous injections of 1 mg pCons significantly delayed the appearance of multiple Abs and nephritis, and dramatically prolonged survival of treated mice. Tolerization with pCons, which contains MHC class I and II T-cell determinants, was shown recently to activate different subsets of inhibitory/cytotoxic CD8+ T cells that regulate both CD4+CD25+ effector T cells and B cells [52]. The tolerogenic 19-mer human CDR1 (hCDR1) peptide designed by Mozes and colleagues was found to interfere with murine lupus disease via the induction of CD4+CD25+ regulatory T cells, and suppression involves CD8+CD28- regulatory T cells [53]. As mentioned above, however, this peptide did not give expected results when evaluated in lupus patients.

Regarding peptides from nuclear autoantigens, Datta and colleagues showed that repeated intravenous or intraperitoneal administration into (SWR×NZB)F1 (SNF1) lupus mice with established glomerulonephritis of a single peptide of histone H4 (sequence 16 to 39), which behaves as a promiscuous T-cell epitope, prolonged survival of treated animals and halted progression of renal disease [54]. The protective properties of another peptide of histone H4 (sequence 71 to 93), accompanied by decreased serum levels of anti-dsDNA IgG2a Abs and of IFN-α [61]. The fact that chronic overproduction of IFNα may represent another marker for disease activity in lupus [62] underlines the interest for the evaluation of such immunoregulatory DNA sequences in SLE patients.

Statins are also considered with great interest since it was demonstrated that these cholesterol-lowering drugs have immunomodulatory properties. Additional studies are required to investigate the potential use of statins in lupus, however, as contradictory results were obtained in NZB/W mice that were given atorvastatin, either orally or intraperitoneally.

**Conclusions**

The current literature search shows a number of promising molecules that are impressively efficient in murine models of lupus. These widely used mouse models are of first importance to identify decisive novel targets, to examine newly developed therapeutic tools and to determine/clarify the mode of action of these new molecules in vivo. Clearly, however, very few of these molecules reach the standard required for evaluating them in clinical trials involving patients with SLE (their solubility and bioavailability, in certain cases, can represent an important limitation). Moreover, because SLE is a syndrome with multiple manifestations, both clinical and biological, management and endpoint determinations of clinical trials for SLE are complex. In particular, a central question concerns the validity of biomarkers (and surrogate markers) and activity indices, which are pertinent for evaluating the performance of lupus trials [63,64].

Important progress has been made recently with the publication of guidelines aimed at facilitating and better controlling clinical trials for SLE [65]. Managing patients with SLE is challenging and new treatments are eagerly awaited. Establishing a valuable and solid data monitoring of patients is as crucial as designing and developing safe and efficient therapeutic molecules or biologicals.

**Competing interests**

Both authors hold patents on P140 peptide (holder: Centre National de la Recherche Scientifique [CNRS], licence to ImmuPharma). FM has received post-doctoral funding from CNRS and ImmuPharma. SM has received fees from...
ImmuPharma to support part of the research activity of her laboratory, the CNRS research unit.

### Additional file

The following Additional file for this article is available online:

**Additional file 1** is a Word document comprising of an expanded version of Table 1, incorporating graphic representations of each compound. See [http://arthritis-research.com/contentsupplementary/ar2711-s1.doc](http://arthritis-research.com/contentsupplementary/ar2711-s1.doc)

### Acknowledgements

The authors thank Olivier Chaloin for help with Additional File 1. Research in the authors’ laboratory is financially supported by the Centre National de la Recherche Scientifique, Région Alsace, and ImmuPharma France. SM thanks the Association Infos Lupus de la Dordogne for a generous gift for lupus research.

### References

1. Kaul A, D’Cruz D, Hughes GRV: **New therapies for systemic lupus erythematosus: has the future arrived?** *Future Rheumatol* 2006, 1:235-247.

2. Liu EH, Siegel RM, Harlan DM, O’Shea JJ: **T-cell therapies: lessons learned and future prospects.** *Nat Immunol* 2007, 8:25-30.

3. Dall’era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Lorenz, HM, Grunke M, Wendler J, Heinzel PA, Kalden JR: **Safety and immunological evaluation of 11-deoxyspergualin in the treatment of glomerulonephritis in MRL lupus mice. I. Immunopathological analyses.** *Arch Dermatol Res* 1995, 287:558-563.

4. Tzallas TG, Kouvelas D: **Topical tacrolimus and pimecrolimus of cutaneous lupus erythematosus in autoimmune MRL-lpr/lpr mice.** *Clin Exp Immunol* 2002, 25:414-415.

5. Fernandez D, Bonilla E, Mirza N, Nland B, Perl A: **Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus.** *Arthritis Rheum* 2006, 54:2983-2988.

6. Xu L, Zhang Z, Yi Y, Kang HK, Datta SK: **Human lupus T cells resist inactivation and escape death by up-regulating COX-2.** *Nat Med* 2004, 10:411-415.

7. Kaul A, D’Cruz D, Hughes GRV: **New therapies for systemic lupus erythematosus: has the future arrived?** *Future Rheumatol* 2006, 1:235-247.

8. Hecht M, Müller M, Lohmann-Matthes ML, Emmendörffer A: In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice. *J Leuk Biol* 1995, 57:42-49.

9. Galindo-Rodriguez G, Bustamante R, Esquível-Nava G, Salazar-Esare D, Vela-Ojeda J, Vadillo-Buenfil M, Avina-Zubieta JA: **Pentoxifylline in the treatment of refractory nephritic syndrome secondary to lupus nephritis.** *J Rheumatol* 2003, 30:2382-2384.

10. Thoegersen ZM, Zinger H, Mozes E: **Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZB×NZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies.** *Ann Rheum Dis* 2003, 62: 341-346.

11. Wu WM, Lin BF, Su YC, Suen JL, Chiang BL: **Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice.** *Scand J Immunol* 2000, 52: 393-400.

12. Wu WM, Suen JL, Lin BF, Chiang BL: **Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice.** *Immunology* 2000, 100:110-118.

13. Akgolgen LD, Bailey DL, Fouts RL, Short L, Bryan N, Evans GF, Sandusky GE, Zuckerman SH, Glassbrook A, Bumol TF: **The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL/lpr/lpr mice.** *Cell Immunol* 1996, 173:55-63.

14. Burgess AD, Evans DT, Mackay IR, Riglar A: **Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus.** *J Clin Lab Immunol* 1984, 13:11-14.

15. Suzuki T, Suzuki N, Engleman EG, Mizushima Y, Sakane T: **Low serum levels of dehydroepiandrosterone sulfonate deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE).** *Clin Exp Immunol* 1995, 99:251-255.

16. Crossie D, Black C, McIntyre L, Royle PL, Thomas S: **Dehydroepiandrosterone for systemic lupus erythematosus.** *Cochrane Database Syst Rev* 2007, 4:CD005114.

17. Abdou NI, Rider V, Greenwell C, Li X, Kimler BF: **Fulvestrant (Faslodex), an estrogen selective receptor downmodulator, in therapy of women with systemic lupus erythematosus.** *Clinical, serologic, bone density, and cell activation marker studies: a double-blind placebo-controlled trial.** *J Rheumatol* 2008, 35:797.

18. Moszkowora L, Lacinova Z, Marek J, Musilova L, Dohnalova A, Dostal C: **Hypertrolpromalin in patients with systemic lupus erythematosus.** *Clin Exp Rheumatol* 2002, 20:807-812.

19. Grimaldi CM: **Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells.** *Curr Opin Rheumatol* 2006, 18:456-461.

20. McMurray RW, Weidensaul D, Allen SH, Walker SE: **Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus.** *J Rheumatol* 1995, 22:2084-2091.

21. Alvarez-Nemegyei J, Coburubias-Cobos A, Escalante-Triay F, Sosa-Munoz J, Miranda JM, Jara LI: **Bromocriptine therapy of systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study.** *Lupus* 1998, 7:414-419.

22. Jara LI, Cruz-Cruz P, Savaeda MA, Medina G, Garca-Flores A, Angeles U, Miranda-Limon JM: **Bromocriptine during pregnancy in systemic lupus erythematosus: a pilot clinical trial.** *Ann NY Acad Sci* 2007, 1110:297-304.

23. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, J oh T, Linnik MD, LJP 394-90-09 Investigator Consortium: **Abetimus sodium for renal flare in systemic lupus erythematosus.** Results of a randomized, controlled phase III trial. *Rheumatology* 2006, 58:2470-2480.

24. Jones DS, Barstad PA, Feild MJ, Hachmann JP, Hayag MS, Hill KW, Iversen GM, Livingston DA, Palanski MS, Tibbetts AR, Yu L, Coutts SM: **Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrasac-o-lipopolysaccharide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis.** *J Med Chem* 1998, 31:2138-2144.

25. Monneaux F, Lozano JM, Patarroyo ME, Briand JP, Muller S: **T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MRL/lpr mice.** *Eur J Immunol* 2003, 33:287-296.

26. Monneaux F, Hoebeke J, Sordet C, Nonn C, Briand JP, Maillebère B, Sibilia J, Muller S: **Selective modulation of CD4 T cells from lupus patients by a promiscuous, protective peptide analogue.** *J Immunol* 2005, 175:5839-5847.

27. Muller S, Monneaux F, Schall N, Rashkov RK, Oparanov BA, Wiesel P, Geiger JM, Zimmer R: **Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus.** Results of an early phase II clinical trial. *Arthritis Rheum* 2008, 58:3873-3883.

28. Bahat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI: An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. *Arthritis...*
Rheumatol 2008, 58:1433-1444.

33. Crispin JC, Tsokos GC: Novel molecular targets in the treatment of systemic lupus erythematosus. Autoimmun Rev 2008, 7:296-261.

34. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dinkahan AH, Medrano-Ramirez G, Morales-Tores JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E: Treatment of rheumatoid arthritis with a syk kinase inhibitor. A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008, 58:3309-3318.

35. Ohori M, Takeuchi M, Maruki R, Nakajima H, Miyake H: FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice. Naunyn-Schmiedebergs Arch Pharmacol 2007, 371:311-316.

36. Deng C, Kaplan MJ, Yang J, Ray D, Zhang Z, McCune WJ, Hanash SM, Richardson BC: Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 2001, 44:397-407.

37. Barber DF, Bartolome A, Hernandez C, Flores JM, Redondo C, Hanash SM, Tsokos GC: Novel molecular targets in the management of SLE and the use of end-points in clinical trials. Lupus 2004, 13:427-431.

38. Crispin JC, Tsokos GC: Trends Immunol 2005, 24:427-431.

39. Zeng H, Hanash SM, Richardson BC: Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 2001, 44:397-407.

40. Berger JD, Wang S, Yin Y, Hau R, Zhang N, Duan X, Zhang Y, Lin W: Treatment of murine lupus using nucleosomal peptide 3247-3255. Eur J Immunol 2007, 37:5382-5386.

41. Wu HY, Staines NA: A deficiency of CD4+CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen. Lupus 2004, 13:192-200.

42. Kang HK, Michaels MA, Berner B, Datta SK: Very low-dose tolerance to nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 2005, 174:3247-3255.

43. Suen JL, Chuang YH, Tsai BY, Yau PM, Chiang BL: Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow-derived dendritic cells. Arthritis Rheum 2004, 50:3250-3259.

44. Amr M, Heilweil M, Ulmansky R, Szafer F, Bar-Tana R, Morel F, Foster MH, Mostoslavsky G, Elizur D, Pizov G, Naparstek Y: Treatment with a laminin-derived peptide suppresses lupus nephritis. J Immunol 2005, 175:5516-5523.

45. Bartos C, DeBenedetti F, Hanash SM, Tsokos GC: Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 2001, 44:397-407.

46. Suen JL, Chuang YH, Tsai BY, Yau PM, Chiang BL: Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow-derived dendritic cells. Arthritis Rheum 2004, 50:3250-3259.

47. Ronnblom L, Alm GV: An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001, 22:427-431.

48. Schifferbauer J, Hahn B, Weisman MH, Simon LS: Bimarkers, surrogate markers, and design of clinical trials of new therapies in systemic lupus erythematosus. Arthritis Rheum 2004, 50:2415-2422.

49. Isenberg D, Gordon C, Merril J, Urowitz M: New therapies in systemic lupus erythematosus — trials, troubles and tribulations ... working towards a solution. Lupus 2008, 17:967-970.

50. Bertiás G, Gordon C, Boumpas DT: Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future — the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus 2008, 17:437-442.